FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010410273> ?p ?o ?g. }

• W2010410273 endingPage "438" @default.
• W2010410273 startingPage "433" @default.
• W2010410273 abstract "This trial was performed to determine the response rate and progression-free and overall survivals of patients with advanced recurrent ovarian cancer who were treated with intraperitoneal cisplatin and 5-fluorouracil.Twenty-four patients with ovarian cancer were entered on this trial and treated with intraperitoneal (ip) cisplatin (DDP) and ip 5-fluorouracil, every 3 weeks for eight cycles. Following iv hydration, the cisplatin and 5-fluorouracil were administered through an ip catheter in 2 liters of 0.9% normal saline with a 4-h dwell.All patients were evaluable for progression-free and overall survival and toxicity analysis, and 22 patients for response. The median age was 59 (range, 35-71); initial disease status included 9 patients with residual disease following chemotherapy prior to entry on this study; 5 patients had progressed, and 10 patients had recurrent disease more than 6 months following initial chemotherapy. Of the 9 patients with residual disease, 1 complete response and 3 partial responses were observed; of 10 patients with recurrent disease, 1 complete and 1 partial response were observed for an overall response rate of 27%. No objective responses were seen in the 7 patients who were platinum-refractory on protocol entry. The median progression-free and overall survivals are 7.0 (range, 0.5-137) and 15.5 (range, 3-147) months, respectively. Toxicity included hypomagnesemia, vomiting, abdominal pain, and mild anemia. Only one patient required a dosage adjustment of cisplatin for a serum creatinine elevation >2.0 mg/dl.We conclude that the combination of ip cisplatin and 5-FU is an effective regimen for patients with residual or relapsed epithelial ovarian cancer with survival durations, response rates, and toxicity profiles that compare favorably with those of other second-line ovarian cancer regimens. Patients who are primarily platinum-refractory are unlikely to benefit from these agents administered into the peritoneal cavity." @default.
• W2010410273 created "2016-06-24" @default.
• W2010410273 creator A5002013432 @default.
• W2010410273 creator A5016932348 @default.
• W2010410273 creator A5018527792 @default.
• W2010410273 creator A5019658293 @default.
• W2010410273 creator A5023917993 @default.
• W2010410273 creator A5027495771 @default.
• W2010410273 creator A5030731004 @default.
• W2010410273 creator A5041200743 @default.
• W2010410273 creator A5043775887 @default.
• W2010410273 creator A5057047127 @default.
• W2010410273 creator A5064172508 @default.
• W2010410273 creator A5065361845 @default.
• W2010410273 creator A5066175992 @default.
• W2010410273 creator A5072745689 @default.
• W2010410273 creator A5075376684 @default.
• W2010410273 date "2000-06-01" @default.
• W2010410273 modified "2023-09-26" @default.
• W2010410273 title "Phase II Trial of Combination Intraperitoneal Cisplatin and 5-Fluorouracil in Previously Treated Patients with Advanced Ovarian Cancer: Long-Term Follow-up" @default.
• W2010410273 cites W1525214537 @default.
• W2010410273 cites W1857437878 @default.
• W2010410273 cites W1916178458 @default.
• W2010410273 cites W1923018909 @default.
• W2010410273 cites W1972722844 @default.
• W2010410273 cites W2014123568 @default.
• W2010410273 cites W2060373580 @default.
• W2010410273 cites W2083616014 @default.
• W2010410273 cites W2103862203 @default.
• W2010410273 cites W2136788689 @default.
• W2010410273 cites W2142114138 @default.
• W2010410273 cites W2173197466 @default.
• W2010410273 cites W2226590642 @default.
• W2010410273 cites W2316501478 @default.
• W2010410273 cites W2430687881 @default.
• W2010410273 cites W4243605909 @default.
• W2010410273 cites W4293241248 @default.
• W2010410273 doi "https://doi.org/10.1006/gyno.2000.5793" @default.
• W2010410273 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10831355" @default.
• W2010410273 hasPublicationYear "2000" @default.
• W2010410273 type Work @default.
• W2010410273 sameAs 2010410273 @default.
• W2010410273 citedByCount "18" @default.
• W2010410273 countsByYear W20104102732012 @default.
• W2010410273 countsByYear W20104102732016 @default.
• W2010410273 countsByYear W20104102732017 @default.
• W2010410273 countsByYear W20104102732018 @default.
• W2010410273 countsByYear W20104102732019 @default.
• W2010410273 countsByYear W20104102732022 @default.
• W2010410273 crossrefType "journal-article" @default.
• W2010410273 hasAuthorship W2010410273A5002013432 @default.
• W2010410273 hasAuthorship W2010410273A5016932348 @default.
• W2010410273 hasAuthorship W2010410273A5018527792 @default.
• W2010410273 hasAuthorship W2010410273A5019658293 @default.
• W2010410273 hasAuthorship W2010410273A5023917993 @default.
• W2010410273 hasAuthorship W2010410273A5027495771 @default.
• W2010410273 hasAuthorship W2010410273A5030731004 @default.
• W2010410273 hasAuthorship W2010410273A5041200743 @default.
• W2010410273 hasAuthorship W2010410273A5043775887 @default.
• W2010410273 hasAuthorship W2010410273A5057047127 @default.
• W2010410273 hasAuthorship W2010410273A5064172508 @default.
• W2010410273 hasAuthorship W2010410273A5065361845 @default.
• W2010410273 hasAuthorship W2010410273A5066175992 @default.
• W2010410273 hasAuthorship W2010410273A5072745689 @default.
• W2010410273 hasAuthorship W2010410273A5075376684 @default.
• W2010410273 hasConcept C121608353 @default.
• W2010410273 hasConcept C126322002 @default.
• W2010410273 hasConcept C141071460 @default.
• W2010410273 hasConcept C2776694085 @default.
• W2010410273 hasConcept C2778239845 @default.
• W2010410273 hasConcept C2778822529 @default.
• W2010410273 hasConcept C2780427987 @default.
• W2010410273 hasConcept C29730261 @default.
• W2010410273 hasConcept C31760486 @default.
• W2010410273 hasConcept C71924100 @default.
• W2010410273 hasConcept C90924648 @default.
• W2010410273 hasConceptScore W2010410273C121608353 @default.
• W2010410273 hasConceptScore W2010410273C126322002 @default.
• W2010410273 hasConceptScore W2010410273C141071460 @default.
• W2010410273 hasConceptScore W2010410273C2776694085 @default.
• W2010410273 hasConceptScore W2010410273C2778239845 @default.
• W2010410273 hasConceptScore W2010410273C2778822529 @default.
• W2010410273 hasConceptScore W2010410273C2780427987 @default.
• W2010410273 hasConceptScore W2010410273C29730261 @default.
• W2010410273 hasConceptScore W2010410273C31760486 @default.
• W2010410273 hasConceptScore W2010410273C71924100 @default.
• W2010410273 hasConceptScore W2010410273C90924648 @default.
• W2010410273 hasIssue "3" @default.
• W2010410273 hasLocation W20104102731 @default.
• W2010410273 hasLocation W20104102732 @default.
• W2010410273 hasOpenAccess W2010410273 @default.
• W2010410273 hasPrimaryLocation W20104102731 @default.
• W2010410273 hasRelatedWork W2106658243 @default.
• W2010410273 hasRelatedWork W2170624001 @default.
• W2010410273 hasRelatedWork W2347888299 @default.
• W2010410273 hasRelatedWork W2353260778 @default.
• W2010410273 hasRelatedWork W2367017737 @default.
• W2010410273 hasRelatedWork W2373869694 @default.

• next